Document Type
Article
Publication Date
12-21-2013
Publication Title
BioMed Central Cancer
Department
Geisel School of Medicine
Abstract
Chk1 inhibitors have emerged as promising anticancer therapeutic agents particularly when combined with antimetabolites such as gemcitabine, cytarabine or hydroxyurea. Here, we address the importance of appropriate drug scheduling when gemcitabine is combined with the Chk1 inhibitor MK-8776, and the mechanisms involved in the schedule dependence.
DOI
10.1186/1471-2407-13-604
Original Citation
Montano R, Thompson R, Chung I, Hou H, Khan N, Eastman A. Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo. BMC Cancer. 2013 Dec 21;13:604. doi: 10.1186/1471-2407-13-604. PMID: 24359526; PMCID: PMC3878047.
Dartmouth Digital Commons Citation
Montano, Ryan; Thompson, Ruth; Chung, Injae; Hou, Huagang; Khan, Nadeem; and Eastman, Alan, "Sensitization of Human Cancer Cells to Gemcitabine by the Chk1 Inhibitor MK-8776: Cell Cycle Perturbation and Impact of Administration Schedule in Vitro and in Vivo" (2013). Dartmouth Scholarship. 578.
https://digitalcommons.dartmouth.edu/facoa/578
Included in
Cancer Biology Commons, Neoplasms Commons, Pharmacology Commons